Analyst consensus rating
Corcept Therapeutics Analyst Rating: Buy
CORT is rated Buy by 4 analysts with a $135.25 target. As of 2026-08-19.
Direct answer
Corcept Therapeutics's consensus rating is Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $135.25.
Forecast evidence checked August 19, 2026.
Get free Corcept Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $120.77
- Average price target
- $135.25
- High price target
- $165.00
- Low price target
- $50.00
- Low target gap
- -58.6%
- Target upside
- +12%
- High target gap
- +36.6%
- Target range width
- 95.2%
- Consensus rating
- Buy
- Analysts
- 4
- Evidence date
- August 19, 2026
- Valid through
- August 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Corcept Therapeutics?
Corcept Therapeutics has a verified Buy consensus. The same dataset has an average price target of $135.25.
How far are Corcept Therapeutics's low and high targets from the recorded price?
The low target implies -58.6%, while the high target implies +36.6%.
How many analysts are included in Corcept Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is Corcept Therapeutics's target upside or downside calculated?
The average target of $135.25 is divided by the recorded price of $120.77, then one is subtracted to produce +12%. This does not guarantee a future return.
When was Corcept Therapeutics's analyst forecast verified?
The data was verified on 2026-08-19. The dataset is valid through 2026-08-26.